Key result
Stem cell-derived extracellular vesicles from adipose tissue or bone marrow reduced the expression of hypertrophic specific markers and inflammatory molecules in an in vitro model of human-induced pluripotent stem cell-derived cardiomyocytes.
Why the study?
Cardiac pathological hypertrophy is a major risk factor for heart failure, and it was hypothesized that extracellular vesicles could reduce cardiac hypertrophy.
Do stem cell-derived extracellular vesicles reduce the expression of hypertrophic markers in an in vitro model of human-induced pluripotent stem cell-derived cardiomyocytes?
Do stem cell-derived extracellular vesicles reduce the expression of hypertrophic markers in an in vitro model of human-induced pluripotent stem cell-derived cardiomyocytes?
Stem cell-derived extracellular vesicles attenuate hypertrophic and inflammatory marker expression in human-induced pluripotent stem cell-derived cardiomyocytes, highlighting their potential as a cell-free therapy for cardiac hypertrophy.
Answers are grounded in this paper and cite their sources.
Provides preliminary in vitro support for extracellular vesicle therapy in hypertrophy; leaves open in vivo efficacy and clinical translation.
Cardiac pathological hypertrophy is the major risk factor that usually progresses to heart failure. We hypothesized that extracellular vesicles (EVs), known to act as important mediators in regulating physiological and pathological functions, could have the potential to reduce the cardiac hypertrophy and the ensuing cardiovascular diseases. Herein, the effects of mesenchymal stem cell-derived extracellular vesicles (EV-MSCs) on cardiac hypertrophy were investigated. EVs were isolated from the secretome of human adipose tissue-derived stem cells (EV-ADSCs) or bone marrow-derived stem cells (EV-BMMSCs). Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were stimulated with AngII and TGF-β1, in absence or presence of EVs. The results showed that exposure of hiPSC-CMs to AngII and TGF-β1 generated in vitro model of hypertrophic cardiomyocytes characterized by increases in surface area , reactive oxygen species production, protein expression of cardiac-specific biomarkers atrial natriuretic factor, migration inhibitory factor, cTnI, COL1A1, Cx43, α-SMA and signalling molecules SMAD2 and NF-kBp50. The presence of EV-ADSCs or EV-BMMSCs in the hiPSC-CM culture along with hypertrophic stimuli reduced the protein expressions of hypertrophic specific markers (ANF, MIF, cTnI, COL1A1) and the gene expressions of IL-6 molecule involved in inflammatory process associated with cardiac hypertrophy and transcription factors SMAD2, SMAD3, cJUN, cFOS with role in cardiomyocyte hypertrophic response induced by AngII and TGF-β1. The EV-ADSCs were more effective in reducing the protein expressions of hypertrophic and inflammatory markers, while EV-BMMSCs in reducing the gene expressions of transcription factors. Notably, neither EV-ADSCs nor EV-BMMSCs induced significant changes in cardiac biomarkers Cx43, α-SMA and fibronectin. These different effects of stem cell-derived EVs could be attributed to their miRNA content: some miRNAs (miR-126-3p, miR-222-3p, miR-30e-5p, miR-181b-5p, miR-124-3p, miR-155-5p, miR-210-3p hsa-miR-221-3p) were expressed in both types of EVs and others only in EV-ADSCs (miR-181a-5p, miR-185-5p, miR-21-5p) or in EV-BMMSCs (miR-143-3p, miR-146a-5p, miR-93-5p), some of these attenuating the cardiac hypertrophy while others enhance it. In conclusion, in hiPSC-CMs the stem cell-derived EVs through their cargo reduced the expression of hypertrophic specific markers and molecules involved in inflammatory process associated with cardiac hypertrophy. The data suggest the EV potential to act as therapeutic mediators to reduce cardiac hypertrophy and possibly the subsequent cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Constantin et al. (2022) studied Cardiac hypertrophy. Mesenchymal stem cell-derived extracellular vesicles (EV-ADSCs or EV-BMMSCs) vs. Hypertrophic stimuli (AngII and TGF-β1) without EVs was evaluated on Protein expressions of hypertrophic specific markers (ANF, MIF, cTnI, COL1A1) and inflammatory molecules. Stem cell-derived extracellular vesicles from adipose tissue or bone marrow reduced the expression of hypertrophic specific markers and inflammatory molecules in an in vitro model of human-induced pluripotent stem cell-derived cardiomyocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: